Keyword: ReGenX Biosciences
Abeona will pay at least $40 million for the right to use the vector in gene therapies against forms of Sanfilippo syndrome and Batten disease.
Gene therapy specialist RegenXBio has added another program to its pipeline, going after Batten disease variant CLN2.
Regenxbio's gene therapy for wet age-related macular degeneration (AMD) reduced the need for in-eye injections of anti-VEGF drugs.
The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline.